Should EMT of cancer cells be understood as epithelial-myeloid transition?

Journal of Cancer

Volumn 5, Issue 2, 2014, Pages 125-132

  Schramm, Henning M ^a  

^a Society for Cancer Research   (Switzerland)

Author keywords

Common clusters of differentiation between cancer cells and cells of the myeloid lineage; Epithelial mesenchymal transition; Epithelial myeloid transition; Macrophage and platelet traits of cancer cells; Osteomimetic properties of cancer cells

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD18 ANTIGEN; CD20 ANTIGEN; CD24 ANTIGEN; CD30 ANTIGEN; CD31 ANTIGEN; CD36 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CD45 ANTIGEN; CD47 ANTIGEN; CD53 ANTIGEN; CD56 ANTIGEN; CD59 ANTIGEN; CD63 ANTIGEN; CD9 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DECAY ACCELERATING FACTOR; DIPEPTIDYL PEPTIDASE IV; FIBRINOGEN RECEPTOR; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LEUKOSIALIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MEMBRANE COFACTOR PROTEIN; MICROSOMAL AMINOPEPTIDASE; TUMOR MARKER;

ARTICLE; BONE MARROW CELL; CANCER CELL; CANCER LOCALIZATION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINEAGE; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; MACROPHAGE; NONHUMAN; OSTEOCLAST; PRIMARY TUMOR; STEM CELL; THROMBOCYTE;

EID: 84893590802     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.8242     Document Type: Article

References (154)

1. Van der Pluijm G: Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone 2011;48(1):37-43.
2. Creighton CJ, Gibbons DL, Kurie JM: The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. Cancer Manag Res 2013;5:187-95.
3. Weber CE, Li NY, Wai PY, Kuo PC: Epithelial-mesenchymal transition, TGF-beta, and osteopontin in wound healing and tissue remodeling after injury. J Burn Care Res 2012;33(3):311-8.
4. Huysentruyt LC, Seyfried TN: Perspectives on the mesenchymal origin of metastatic cancer. Cancer Metastasis Rev 2010;29(4):695-707.
5. Huysentruyt LC, Mukherjee P, Banerjee D, Shelton LM, Seyfried TN: Metastatic cancer cells with macrophage properties: evidence from a new murine tumor model. Int J Cancer 2008;123(1):73-84.
6. Ruff MR, Pert CB: Small cell carcinoma of the lung: macrophage-specific antigens suggest hemopoietic stem cell origin. Science 1984;225(4666):1034-6.
7. Schramm HM: Extraterritorial osteoclast traits of primary cancer cells. Journal of Solid tumors 2011;1(2):65-79.
8. Shabo I, Svanvik J: Expression of macrophage antigens by tumor cells. Adv Exp Med Biol 2011;714:141-50.
9. Timar J, Tovari J, Raso E, Meszaros L, Bereczky B, Lapis K: Platelet-mimicry of cancer cells: epiphenomenon with clinical significance. Oncology 2005;69(3):185-201.
10. Pawelek JM: Tumour-cell fusion as a source of myeloid traits in cancer. Lancet Oncol 2005;6(12):988-93.
11. Pawelek J, Chakraborty A, Lazova R, Yilmaz Y, Cooper D, Brash D, Handerson T: Co-opting macrophage traits in cancer progression: a consequence of tumor cell fusion? Contrib Microbiol 2006;13:138-55
12. Pilz GA, Braun J, Ulrich C, Felka T, Warstat K, Ruh M, Schewe B, Abele H, Larbi A, Aicher WK: Human mesenchymal stromal cells express CD14 cross-reactive epitopes. Cytometry A 2011;79(8):635-45.
13. Koeneman KS, Yeung F, Chung LW: Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999;39(4):246-61.
14. Bellahcene A, Merville MP, Castronovo V: Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res 1994;54(11):2823-6.
15. Gillespie MT, Thomas RJ, Pu ZY, Zhou H, Martin TJ, Findlay DM: Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer 1997;73(6):812-5.
16. Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS: Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 2008;8(3):212-26.
17. Huang WC, Xie Z, Konaka H, Sodek J, Zhau HE, Chung LW: Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res 2005;65(6):2303-13.
18. Chaplet M, De Leval L, Waltregny D, Detry C, Fornaciari G, Bevilacqua G, Fisher LW, Castronovo V, Bellahcene A: Dentin matrix protein 1 is expressed in human lung cancer. J Bone Miner Res 2003;18(8):1506-12.
19. Yamashita M, Otsuka F, Mukai T, Yamanaka R, Otani H, Matsumoto Y, Nakamura E, Takano M, Sada KE, Makino H: Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling. Regul Pept 2010;162(1-3):99-108.
20. Neri D, Supuran CT: Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10(10):767-77.
21. Adams LM, Warburton MJ, Hayman AR: Human breast cancer cell lines and tissues express tartrate-resistant acid phosphatase (TRAP). Cell Biol Int 2007;31(2):191-5.
22. Schramm HM: The cross-over of anticancer agents wit osteoclast activities. Current Cancer Therapy Reviews 2011;7(4):290-302.
23. Fujikawa Y, Sabokbar A, Neale S, Athanasou NA: Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. Ann Rheum Dis 1996;55(11):816-22.
24. Gaiser MR, Lammermann T, Feng X, Igyarto BZ, Kaplan DH, Tessarollo L, Germain RN, Udey MC: Cancer-associated epithelial cell adhesion molecule (EpCAM; CD326) enables epidermal Langerhans cell motility and migration in vivo. Proc Natl Acad Sci U S A 2012;109(15):E889-97.
25. Wykes M, MacDonald KP, Tran M, Quin RJ, Xing PX, Gendler SJ, Hart DN, McGuckin MA: MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells. J Leukoc Biol 2002;72(4):692-701.
26. Tang A, Amagai M, Granger LG, Stanley JR, Udey MC: Adhesion of epidermal Langerhans cells to keratinocytes mediated by E-cadherin. Nature 1993;361(6407):82-5.
27. Fang TC, Otto WR, Rao J, Jeffery R, Hunt T, Alison MR, Cook HT, Wright NA, Poulsom R: Haematopoietic lineage-committed bone marrow cells, but not cloned cultured mesenchymal stem cells, contribute to regeneration of renal tubular epithelium after HgCl 2 -induced acute tubular injury. Cell Prolif 2008;41(4):575-91.
28. Fang TC, Alison MR, Cook HT, Jeffery R, Wright NA, Poulsom R: Proliferation of bone marrow-derived cells contributes to regeneration after folic acid-induced acute tubular injury. J Am Soc Nephrol 2005;16(6):1723-32.
29. Romani N, Clausen BE, Stoitzner P: Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol Rev 2010;234(1):120-41.
30. Modi BG, Neustadter J, Binda E, Lewis J, Filler RB, Roberts SJ, Kwong BY, Reddy S, Overton JD, Galan A, Tigelaar R, Cai L, Fu P, Shlomchik M, Kaplan DH, Hayday A, Girardi M: Langerhans cells facilitate epithelial DNA damage and squamous cell carcinoma. Science 2012;335(6064):104-8.
31. Kaplan DH, Jenison MC, Saeland S, Shlomchik WD, Shlomchik MJ: Epidermal langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity 2005;23(6):611-20.
32. Rivollier A, Mazzorana M, Tebib J, Piperno M, Aitsiselmi T, Rabourdin-Combe C, Jurdic P, Servet-Delprat C: Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 2004;104(13):4029-37.
33. Schramm HM: The role of the osteoimmune axis in the inflammation of the inner auditory ear and with regard to the putative anticarcinogenetic principle: part 2. Inflamm Allergy Drug Targets 2010;9(2):120-9.
34. Seluanov A, Hine C, Azpurua J, Feigenson M, Bozzella M, Mao Z, Catania KC, Gorbunova V: Hypersensitivity to contact inhibition provides a clue to cancer resistance of naked mole-rat. Proc Natl Acad Sci U S A 2009;106(46):19352-7.
35. Manov I, Hirsh M, Iancu TC, Malik A, Sotnichenko N, Band M, Avivi A, Shams I: Pronounced cancer resistance in a subterranean rodent, the blind mole-rat, Spalax: in vivo and in vitro evidence. BMC Biol 2013;11:91.
36. Kischel P, Bellahcene A, Deux B, Lamour V, Dobson R, E DEP, Clezardin P, Castronovo V: Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases. Anticancer Res 2012;32(12):5211-20.
37. Carloni V, Mazzocca A, Mello T, Galli A, Capaccioli S: Cell fusion promotes chemoresistance in metastatic colon carcinoma. Oncogene 2012;32(21):2649-60.
38. Buim ME, Lourenco SV, Carvalho KC, Cardim R, Pereira C, Carvalho AL, Fregnani JH, Soares FA: Downregulation of CD9 protein expression is associated with aggressive behavior of oral squamous cell carcinoma. Oral Oncol 2010;46(3):166-71.
39. Okochi H, Kato M, Nashiro K, Yoshie O, Miyazono K, Furue M: Expression of tetra-spans transmembrane family (CD9, CD37, CD53, CD63, CD81 and CD82) in normal and neoplastic human keratinocytes: an association of CD9 with alpha 3 beta 1 integrin. Br J Dermatol 1997;137(6):856-63.
40. Guillemin GJ, Brew BJ: Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol 2004;75(3):388-97.
41. Abdou AG: CD10 expression in tumour and stromal cells of bladder carcinoma: an association with bilharziasis. Apmis 2007;115(11):1206-18.
42. Omran OM: CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma. J Environ Pathol Toxicol Oncol 2012;31(3):203-12.
43. Leccia F, Nardone A, Corvigno S, Vecchio LD, De Placido S, Salvatore F, Veneziani BM: Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous myoepithelial phenotypes. Cytometry A 2012;81(11):960-72.
44. Calvo F, Martin PM, Jabrane N, De Cremoux P, Magdelenat H: Human breast cancer cells share antigens with the myeloid monocyte lineage. Br J Cancer 1987;56(1):15-9.
45. Schmitt C, Voegelin M, Marin A, Schmitt M, Schegg F, Henon P, Guenot D, Tarnus C: Selective aminopeptidase-N (CD13) inhibitors with relevance to cancer chemotherapy. Bioorg Med Chem 2013;21(7):2135-44.
46. Lobba AR, Forni MF, Carreira AC, Sogayar MC: Differential expression of CD90 and CD14 stem cell markers in malignant breast cancer cell lines. Cytometry A 2012;81(12):1084-91.
47. Koh YW, Lee HJ, Ahn JH, Lee JW, Gong G: Expression of Lewis X is associated with poor prognosis in triple-negative breast cancer. Am J Clin Pathol 2013;139(6):746-53.
48. Athanasou NA, Quinn J: Immunophenotypic differences between osteoclasts and macrophage polykaryons: immunohistological distinction and implications for osteoclast ontogeny and function. J Clin Pathol 1990;43(12):997-1003.
49. Ghislin S, Obino D, Middendorp S, Boggetto N, Alcaide-Loridan C, Deshayes F: LFA-1 and ICAM-1 expression induced during melanoma-endothelial cell co-culture favors the transendothelial migration of melanoma cell lines in vitro. BMC Cancer 2012;12:455.
50. Yang SL, Tang YM, Shen HQ, Qian BQ, Song H, Shi SW, Ning BT, Chen YH, Xu WQ: [Expression of leucocyte cell-surface antigens on colon cancer cell line HR8348]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2004;33(2):118-20.
51. Magnoni C, Giudice S, Pellacani G, Bertazzoni G, Longo C, Veratti E, Morini D, Benassi L, Vaschieri C, Azzoni P, De Pol A, Seidenari S, Tomasi A, Pollio A, Ponti G: Stem Cell Properties in Cell Cultures From Different Stage of Melanoma Progression. Appl Immunohistochem Mol Morphol 2013.
52. Buck K, Hug S, Seibold P, Ferschke I, Altevogt P, Sohn C, Schneeweiss A, Burwinkel B, Jager D, Flesch-Janys D, Chang-Claude J, Marme F: CD24 polymorphisms in breast cancer: impact on prognosis and risk. Breast Cancer Res Treat 2013;137(3):927-37.
53. Soave DF, Oliveira da Costa JP, da Silveira GG, Ianez RC, de Oliveira LR, Lourenco SV, Ribeiro-Silva A: CD44/CD24 immunophenotypes on clinicopathologic features of salivary glands malignant neoplasms. Diagn Pathol 2013;8:29.
54. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M, Zeller Y, Vestweber D, Stahel R, Sammar M, Altevogt P: CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997;89(9):3385-95.
55. Caly Dde N, Viana A, Rapoport A, Dedivitis RA, Curioni OA, Cernea CR, Brandao LG: Indications and pitfalls of immunohistochemistry in head and neck cancer. Braz J Otorhinolaryngol 2013;79(1):75-81.
56. Woodhead VE, Binks MH, Chain BM, Katz DR: From sentinel to messenger: an extended phenotypic analysis of the monocyte to dendritic cell transition. Immunology 1998;94(4):552-9.
57. Tang DG, Chen YQ, Newman PJ, Shi L, Gao X, Diglio CA, Honn KV: Identification of PECAM-1 in solid tumor cells and its potential involvement in tumor cell adhesion to endothelium. J Biol Chem 1993;268(30):22883-94.
58. Uray IP, Liang Y, Hyder SM: Estradiol down-regulates CD36 expression in human breast cancer cells. Cancer Lett 2004;207(1):101-7.
59. Vallbo C, Wang W, Damber JE: The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer. BJU Int 2004;93(9):1339-43.
60. Chen M, Pych E, Corpron C, Harmon CM: Regulation of CD36 expression in human melanoma cells. Adv Exp Med Biol 2002;507:337-42.
61. Karimi-Busheri F, Zadorozhny V, Li T, Lin H, Shawler DL, Fakhrai H: Pivotal role of CD38 biomarker in combination with CD24, EpCAM, and ALDH for identification of H460 derived lung cancer stem cells. J Stem Cells 2011;6(1):9-20.
62. Perenkov AD, Novikov DV, Sakharnov NA, Aliasova AV, Utkin OV, Baryshnikov A, Novikov VV: [Heterogeneous expression of CD38 gene in tumor tissue in patients with colorectal cancer]. Mol Biol (Mosk) 2012;46(5):786-91.
63. Yamaguchi H, Tanaka F, Sadanaga N, Ohta M, Inoue H, Mori M: Stimulation of CD40 inhibits Fas- or chemotherapy-mediated apoptosis and increases cell motility in human gastric carcinoma cells. Int J Oncol 2003;23(6):1697-702.
64. Elmetwali T, Searle PF, McNeish I, Young LS, Palmer DH: CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus. Mol Cancer 2010;9:52.
65. Merono A, Lucena C, Lopez A, Garrido JJ, Perez de LL, Llanes D: Immunohistochemical analysis of beta3 integrin (CD61): expression in pig tissues and human tumors. Histol Histopathol 2002;17(2):347-52.
66. Anderson KM, Guinan P, Rubenstein M: The effect of normoxia and hypoxia on a prostate (PC-3) CD44/CD41 cell side fraction. Anticancer Res 2011;31(2):487-94.
67. Gekas C, Graf T: CD41 expression marks myeloid-biased adult hematopoietic stem cells and increases with age. Blood 2013;121(22):4463-72.
68. Balikova A, Jaager K, Viil J, Maimets T, Kadaja-Saarepuu L: Leukocyte marker CD43 promotes cell growth in co-operation with beta-catenin in non-hematopoietic cancer cells. Int J Oncol 2012;41(1):299-309.
69. Goodison S, Urquidi V, Tarin D: CD44 cell adhesion molecules. Mol Pathol 1999;52(4):189-96.
70. Melotti A, Daga A, Marubbi D, Zunino A, Mutti L, Corte G: In vitro and in vivo characterization of highly purified human mesothelioma derived cells. BMC Cancer 2010;10:54.
71. Nuutila J, Jalava-Karvinen P, Hohenthal U, Kotilainen P, Pelliniemi TT, Nikoskelainen J, Lilius EM: Use of complement regulators, CD35, CD46, CD55, and CD59, on leukocytes as markers for diagnosis of viral and bacterial infections. Hum Immunol 2013;74(5):522-30.
72. Lee G, Zhu M, Ge B, Potzold S: Widespread expressions of immunoglobulin superfamily proteins in cancer cells. Cancer Immunol Immunother 2011;61(1):89-99.
73. Han X, Sterling H, Chen Y, Saginario C, Brown EJ, Frazier WA, Lindberg FP, Vignery A: CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J Biol Chem 2000;275(48):37984-92.
74. Jockers JJ, Novak N: Different expression of adhesion molecules and tetraspanins of monocytes of patients with atopic eczema. Allergy 2006;61(12):1419-22.
75. Clezardin P, Frappart L, Clerget M, Pechoux C, Delmas PD: Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res 1993;53(6):1421-30.
76. Hu Y, Wu G, Rusch M, Lukes L, Buetow KH, Zhang J, Hunter KW: Integrated cross-species transcriptional network analysis of metastatic susceptibility. Proc Natl Acad Sci U S A 2012;109(8):3184-9.
77. Ferreira-Facio CS, Milito C, Botafogo V, Fontana M, Thiago LS, Oliveira E, da Rocha-Filho AS, Werneck F, Forny DN, Dekermacher S, de Azambuja AP, Ferman SE, de Faria PA, Land MG, Orfao A, Costa ES: Contribution of multiparameter flow cytometry immunophenotyping to the diagnostic screening and classification of pediatric cancer. PLoS One 2013;8(3):e55534.
78. Anguille S, Lion E, Tel J, de Vries IJ, Coudere K, Fromm PD, Van Tendeloo VF, Smits EL, Berneman ZN: Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One 2012;7(12):e51851.
79. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M: Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003;40(2-4):109-23.
80. Husheem M, Nyman JK, Vaaraniemi J, Vaananen HK, Hentunen TA: Characterization of circulating human osteoclast progenitors: development of in vitro resorption assay. Calcif Tissue Int 2005;76(3):222-30.
81. Lindeman GJ, Visvader JE: Insights into the cell of origin in breast cancer and breast cancer stem cells. Asia Pac J Clin Oncol 2010;6(2):89-97.
82. Kim DH, Kwon MS: Role of fine needle aspiration cytology, cell block preparation and CD63, P63 and CD56 immunostaining in classifying the specific tumor type of the lung. Acta Cytol 2010;54(1):55-9.
83. Gottfried E, Kunz-Schughart LA, Weber A, Rehli M, Peuker A, Muller A, Kastenberger M, Brockhoff G, Andreesen R, Kreutz M: Expression of CD68 in non-myeloid cell types. Scand J Immunol 2008;67(5):453-63.
84. Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non-macrophage derived tumours in cytological specimens. J Clin Pathol 1993;46(4):334-6.
85. Xiao Y, Song JY, de Vries TJ, Fatmawati C, Parreira DB, Langenbach GE, Babala N, Nolte MA, Everts V, Borst J: Osteoclast precursors in murine bone marrow express CD27 and are impeded in osteoclast development by CD70 on activated immune cells. Proc Natl Acad Sci U S A 2013;110(30):12385-90.
86. Law CL, McEarchern JA, Grewal IS: Novel antibody-based therapeutic agents targeting CD70: a potential approach for treating Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009;9(1):90-3.
87. Rust S, Guillard S, Sachsenmeier K, Hay C, Davidson M, Karlsson A, Karlsson R, Brand E, Lowne D, Elvin J, Flynn M, Kurosawa G, Hollingsworth R, Jermutus L, Minter R: Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer cell type. Mol Cancer 2013;12:11.
88. Shechter R, Miller O, Yovel G, Rosenzweig N, London A, Ruckh J, Kim KW, Klein E, Kalchenko V, Bendel P, Lira SA, Jung S, Schwartz M: Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity 2013;38(3):555-69.
89. Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth MJ, Stagg J: CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A 2013;110(27):11091-6.
90. Takahashi M, Takahashi M, Shinohara F, Takada H, Rikiishi H: Effects of superantigen and lipopolysaccharide on induction of CD80 through apoptosis of human monocytes. Infect Immun 2001;69(6):3652-7.
91. Chen C, Qu QX, Shen Y, Mu CY, Zhu YB, Zhang XG, Huang JA: Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: a potential mechanism of immune escape. Cancer Lett 2012;317(1):99-105.
92. Iwai K, Ishii M, Ohshima S, Miyatake K, Saeki Y: Expression and function of transmembrane-4 superfamily (tetraspanin) proteins in osteoclasts: reciprocal roles of Tspan-5 and NET-6 during osteoclastogenesis. Allergol Int 2007;56(4):457-63.
93. Loser K, Scherer A, Krummen MB, Varga G, Higuchi T, Schwarz T, Sharpe AH, Grabbe S, Bluestone JA, Beissert S: An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice. J Immunol 2005;174(9):5298-305.
94. Hildenbrand R, Schaaf A, Dorn-Beineke A, Allgayer H, Sutterlin M, Marx A, Stroebel P: Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact. Histol Histopathol 2009;24(7):869-77.
95. Eastman BM, Jo M, Webb DL, Takimoto S, Gonias SL: A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen. Cell Signal 2012;24(9):1847-55.
96. Metzger W, Schimmelpfennig L, Schwab B, Sossong D, Dorst N, Bubel M, Gorg A, Putz N, Wennemuth G, Pohlemann T, Oberringer M: Expansion and differentiation of human primary osteoblasts in two- and three-dimensional culture. Biotech Histochem 2012;88(2):86-102.
97. Feller N, Kelder A, Westra G, Ossenkoppele GJ, Schuurhuis GJ: Positive selection for CD90 as a purging option in acute myeloid leukemia stem cell transplants. Cytometry B Clin Cytom 2008;74(1):9-16.
98. Dabrowski A, Osada J, Dabrowska MI, Wereszczynska-Siemiatkowska U: Monocyte subsets and natural killer cells in acute pancreatitis. Pancreatology 2008;8(2):126-34.
99. Abbott RJ, Spendlove I, Roversi P, Fitzgibbon H, Knott V, Teriete P, McDonnell JM, Handford PA, Lea SM: Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55. J Biol Chem 2007;282(30):22023-32.
100. Mori K, Nishimura M, Tsurudome M, Ito M, Nishio M, Kawano M, Kozuka Y, Yamashita Y, Komada H, Uchida A, Ito Y: The functional interaction between CD98 and CD147 in regulation of virus-induced cell fusion and osteoclast formation. Med Microbiol Immunol 2004;193(4):155-62.
101. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Kawashima O, Kamide Y, Ishizuka T, Kanai Y, Nakajima T, Mori M: CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases. Ann Surg Oncol 2009;16(12):3473-81.
102. Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN: Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res 2013;19(1):170-82.
103. Yu HK, Lee HJ, Choi HN, Ahn JH, Choi JY, Song HS, Lee KH, Yoon Y, Yi LS, Kim JS, Kim SJ, Kim TJ: Characterization of CD45-/CD31+/CD105+ Circulating Cells in the Peripheral Blood of Patients with Gynecologic Malignancies. Clin Cancer Res 2013.
104. Lin KY, Lu D, Hung CF, Peng S, Huang L, Jie C, Murillo F, Rowley J, Tsai YC, He L, Kim DJ, Jaffee E, Pardoll D, Wu TC: Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res 2007;67(4):1832-41.
105. Oshima T, Sato S, Kato J, Ito Y, Watanabe T, Tsuji I, Hori A, Kurokawa T, Kokubo T: Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers. Mol Cancer 2013;12:60.
106. Miao X, Yang ZL, Xiong L, Zou Q, Yuan Y, Li J, Liang L, Chen M, Chen S: Nectin-2 and DDX3 are biomarkers for metastasis and poor prognosis of squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. Int J Clin Exp Pathol 2013;6(2):179-90.
107. Pende D, Castriconi R, Romagnani P, Spaggiari GM, Marcenaro S, Dondero A, Lazzeri E, Lasagni L, Martini S, Rivera P, Capobianco A, Moretta L, Moretta A, Bottino C: Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood 2006;107(5):2030-6.
108. Ide H, Seligson DB, Memarzadeh S, Xin L, Horvath S, Dubey P, Flick MB, Kacinski BM, Palotie A, Witte ON: Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. Proc Natl Acad Sci U S A 2002;99(22):14404-9.
109. Morandi A, Barbetti V, Riverso M, Dello Sbarba P, Rovida E: The colony-stimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines. PLoS One 2011;6(11):e27450.
110. Sinha N, Mukhopadhyay S, Das DN, Panda PK, Bhutia SK: Relevance of cancer initiating/stem cells in carcinogenesis and therapy resistance in oral cancer. Oral Oncol 2013;49(9):854-62.
111. Gattei V, Aldinucci D, Quinn JM, Degan M, Cozzi M, Perin V, Iuliis AD, Juzbasic S, Improta S, Athanasou NA, Ashman LK, Pinto A: Human osteoclasts and preosteoclast cells (FLG 29.1) express functional c-kit receptors and interact with osteoblast and stromal cells via membrane-bound stem cell factor. Cell Growth Differ 1996;7(6):753-63.
112. Predina J, Eruslanov E, Judy B, Kapoor V, Cheng G, Wang LC, Sun J, Moon EK, Fridlender ZG, Albelda S, Singhal S: Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci U S A 2013;110(5):E415-24.
113. Puri S, Puri S, Mahapatra AK, Hussain E, Sarkar C, Sinha S, Joshi BH: A review of studies on targeting interleukin 4 receptor for central nervous system malignancy. Curr Mol Med 2009;9(6):732-9.
114. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabro E, Pastorino U, Sozzi G: Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 2009;106(38):16281-6.
115. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J, Jr., Chang HY, van de Rijn M, Shortliffe L, Weissman IL: Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A 2009;106(33):14016-21.
116. Bonetti MI, Pieri L, Domenici L, Urbani S, Romano G, Aldinucci A, Ballerini C, Monici M, Saccardi R, Basile V, Bosi A, Romagnoli P: Dendritic cells with lymphocyte-stimulating activity differentiate from human CD133 positive precursors. Blood 2011;117(15):3983-95.
117. Bellarosa D, Bressan A, Bigioni M, Parlani M, Maggi CA, Binaschi M: SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line. Int J Oncol 2012;41(4):1486-94.
118. Tang Q, Jiang D, Shao Z, Martinez Gomez JM, Schwarz H: Species difference of CD137 ligand signaling in human and murine monocytes. PLoS One 2011;6(1):e16129.
119. Wang Z, Yan X: CD146, a multi-functional molecule beyond adhesion. Cancer Lett 2013;330(2):150-62.
120. Goodale D, Phay C, Brown W, Gray-Statchuk L, Furlong P, Lock M, Chin-Yee I, Keeney M, Allan AL: Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer. Cytometry B Clin Cytom 2009;76(2):107-17.
121. Zhang H, Zhang J, Wang Z, Lu D, Feng J, Yang D, Chen X, Yan X: CD146 is a potential marker for the diagnosis of malignancy in cervical and endometrial cancer. Oncol Lett 2013;5(4):1189-1194.
122. Imbert AM, Garulli C, Choquet E, Koubi M, Aurrand-Lions M, Chabannon C: CD146 expression in human breast cancer cell lines induces phenotypic and functional changes observed in Epithelial to Mesenchymal Transition. PLoS One 2012;7(8):e43752.
123. Pinheiro C, Reis RM, Ricardo S, Longatto-Filho A, Schmitt F, Baltazar F: Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol 2010;2010:427694.
124. Casado JG, Pawelec G, Morgado S, Sanchez-Correa B, Delgado E, Gayoso I, Duran E, Solana R, Tarazona R: Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother 2009;58(9):1517-26.
125. Avila-Moreno F, Lopez-Gonzalez JS, Galindo-Rodriguez G, Prado-Garcia H, Bajana S, Sanchez-Torres C: Lung squamous cell carcinoma and adenocarcinoma cell lines use different mediators to induce comparable phenotypic and functional changes in human monocyte-derived dendritic cells. Cancer Immunol Immunother 2006;55(5):598-611.
126. Tang J, Zhang L, She X, Zhou G, Yu F, Xiang J, Li G: Inhibiting CD164 expression in colon cancer cell line HCT116 leads to reduced cancer cell proliferation, mobility, and metastasis in vitro and in vivo. Cancer Invest 2012;30(5):380-9.
127. Watt SM, Buhring HJ, Rappold I, Chan JY, Lee-Prudhoe J, Jones T, Zannettino AC, Simmons PJ, Doyonnas R, Sheer D, Butler LH: CD164, a novel sialomucin on CD34(+) and erythroid subsets, is located on human chromosome 6q21. Blood 1998;92(3):849-66.
128. Ofori-Acquah SF, King JA: Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res 2008;151(3):122-8.
129. Levesque MC, Heinly CS, Whichard LP, Patel DD: Cytokine-regulated expression of activated leukocyte cell adhesion molecule (CD166) on monocyte-lineage cells and in rheumatoid arthritis synovium. Arthritis Rheum 1998;41(12):2221-9.
130. Schafer H, Dieckmann C, Korniienko O, Moldenhauer G, Kiefel H, Salnikov A, Kruger A, Altevogt P, Sebens S: Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. Cancer Lett 2012;319(1):66-82.
131. Xing Q, de Vos P, Faas MM, Ye Q, Ren Y: LPS promotes pre-osteoclast activity by up-regulating CXCR4 via TLR-4. J Dent Res 2011;90(2):157-62.
132. Gorczynski RM, Chen Z, Diao J, Khatri I, Wong K, Yu K, Behnke J: Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. Breast Cancer Res Treat 2010;123(2):405-15.
133. Leroy X, Buisine MP, Leteurtre E, Aubert S, Buob D, Porchet N, Copin MC: [MUC1 (EMA): A key molecule of carcinogenesis?]. Ann Pathol 2006;26(4):257-66.
134. Huang G, Wen Q, Zhao Y, Gao Q, Bai Y: NF-kappaB plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment. PLoS One 2013;8(4):e61602.
135. Sznol M, Chen L: Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer--Response. Clin Cancer Res 2013.
136. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC: Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 2007;171(2):386-95.
137. Zenger S, Ek-Rylander B, Andersson G: Biogenesis of tartrate-resistant acid phosphatase isoforms 5a and 5b in stably transfected MDA-MB-231 breast cancer epithelial cells. Biochim Biophys Acta 2010;1803(5):598-607.
138. Honig A, Rieger L, Kapp M, Krockenberger M, Eck M, Dietl J, Kammerer U: Increased tartrate-resistant acid phosphatase (TRAP) expression in malignant breast, ovarian and melanoma tissue: an investigational study. BMC Cancer 2006;6:199.
139. Santini D PG, Roato I, Godio L, Pantano F, Grasso D, Russo A, Vincenzi B, Fratto ME, Sabbatini R, Della Pepa C, Porta C, Del Conte A, Schiavon G, Berruti A, Tomasino RM, Papotti M, Papapietro N, Onetti Muda A, Denaro V, Tonini G: Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol 2010;226(3):780-4.
140. Littlewood-Evans AJ, Bilbe G, Bowler WB, Farley D, Wlodarski B, Kokubo T, Inaoka T, Sloane J, Evans DB, Gallagher JA: The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 1997;57(23):5386-90.
141. Takayanagi H: Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med (Berl) 2005;83(3):170-9.
142. Shabo I, Olsson H, Stal O, Svanvik J: Breast Cancer Expression of DAP12 is Associated With Skeletal and Liver Metastases and Poor Survival. Clin Breast Cancer 2013;13(5):371-7.
143. Wang D, Huang P, Zhu B, Sun L, Huang Q, Wang J: Induction of estrogen receptor alpha-36 expression by bone morphogenetic protein 2 in breast cancer cell lines. Mol Med Rep 2012;6(3):591-6.
144. Oksala N, Levula M, Pelto-Huikko M, Kytomaki L, Soini JT, Salenius J, Kahonen M, Karhunen PJ, Laaksonen R, Parkkila S, Lehtimaki T: Carbonic anhydrases II and XII are up-regulated in osteoclast-like cells in advanced human atherosclerotic plaques-Tampere Vascular Study. Ann Med 2010;42(5):360-70.
145. Monego G, Lauriola L, Ramella S, D'Angelillo RM, Lanza P, Granone P, Ranelletti FO: Parathyroid hormone-related peptide and parathyroid hormone-related peptide receptor type 1 expression in human lung adenocarcinoma. Chest 2010;137(4):898-908.
146. Nakashima M, Nakayama T, Ohtsuru A, Fukada E, Niino D, Yamazumi K, Naito S, Ito M, Sekine I: Expression of parathyroid hormone (PTH)-related peptide (PthrP) and PTH/PTHrP receptor in osteoclast-like giant cells. Pathol Res Pract 2003;199(2):85-92.
147. Massfelder T, Lang H, Schordan E, Lindner V, Rothhut S, Welsch S, Simon-Assmann P, Barthelmebs M, Jacqmin D, Helwig JJ: Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von Hippel-Lindau tumor suppressor gene. Cancer Res 2004;64(1):180-8.
148. Lupp A, Klenk C, Rocken C, Evert M, Mawrin C, Schulz S: Immunohistochemical identification of the PTHR1 parathyroid hormone receptor in normal and neoplastic human tissues. Eur J Endocrinol 2010;162(5):979-86.
149. Sato Y, Goto Y, Narita N, Hoon DS: Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenviron 2009;2 Suppl 1:205-14.
150. Rao VH, Kandel A, Lynch D, Pena Z, Marwaha N, Deng C, Watson P, Hansen LA: A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion. Oncogene 2011;31(23):2888-98.
151. Frohlich C, Nehammer C, Albrechtsen R, Kronqvist P, Kveiborg M, Sehara-Fujisawa A, Mercurio AM, Wewer UM: ADAM12 produced by tumor cells rather than stromal cells accelerates breast tumor progression. Mol Cancer Res 2011;9(11):1449-61.
152. Yagi M, Miyamoto T, Toyama Y, Suda T: Role of DC-STAMP in cellular fusion of osteoclasts and macrophage giant cells. J Bone Miner Metab 2006;24(5):355-8.
153. Engin F, Lee B: NOTCHing the bone: insights into multi-functionality. Bone 2010;46(2):274-80.
154. Guo S, Liu M, Gonzalez-Perez RR: Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta 2011;1815(2):197-213.